New research project on metrology of nanomedicine (MetrINo) funded
We are pleased to inform you that project 22HLT04/h03-MetrINO-Metrology for innovative nanotherapeutics in which we participate as a partner has been selected for funding’s by EURAMET under the European Partnership on Metrology 2022 call.
MetrINo responds to the immediate metrological needs expressed by industry, regulatory agencies and policymakers to develop, and validate traceable measurement methods and reference materials for the assessment of the critical quality attributes of nanotherapeutics. The project focus on clinical formulations, including synthetic lipid-based and metal oxide nanoparticles used for localised cancer treatment, gene therapy, vaccines (COVID-19) or as contrast agents. Candidate reference materials will be developed and used for measurement control. MetrINo will develop and validate traceable methods to measure nanoparticle physical properties, biotransformation in biological media, and methods for their identification and quantification in cells and tissues.
The project is coordinated by the LNE, Laboratoire national de métrologie et d'essais. The international consortium involving 10 countries is composed by 10 national metrology institutes or designated institutes (LNE, BAM, PTB, RISE, SMD, TUBITAK, INRIM, LGC, NPL, NRC), the ETPN nanomedicine association; 3 research and technology organisations (SINTEF, EMPA, CEA), 3 academic partners (UPv, OVGU, UGent) 1 hospital (OGSA), 2 pharmaceutical industries (NanoPET, NanoBiotix) and 1 SME (Curadigm) that are key experts in the field of nanomedicine. MetrINo is further supported by more than 20 international stakeholders.
